Sep 28

PQA 02 - Lung Cancer/Thoracic Malignancies, Patient Reported Outcomes/QoL/Survivorship, Pediatric Cancer

2516 - Magnetic Resonance can be Used in Guiding Hypo-Fractionated Radiotherapy for Non-Small Cell Lung Cancer

04:45pm - 06:00pm PT

Hall F

Screen: 14

Presenter(s)

Ligang Xing, MD, RT - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Jinan, Shandong

L. Xing; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Jinan, Shandong, China

Purpose/Objective(s): To assess the viability of MR-guided hypo-fractionated radiotherapy for non-small cell lung cancer (NSCLC) and evaluate its effectiveness and safety.

Materials/Methods: We looked back at data from 60 patients with non-small cell lung cancer who had hypo-fractionated radiotherapy. The descriptions covered the patients' treatment, planning target volume (PTV), radiation dose to PTV, organ at risk (OAR) doses, positioning errors, treatment effectiveness, and adverse reactions. We employed COX regression analysis to explore the factors influencing progression-free survival (PFS) in patients undergoing magnetic resonance-guided radiotherapy (MRgRT) across different stages of cancer.

Results: All patients completed treatment without any machine malfunctions. Six out of 60 patients had changes to their baseline plan, with two showing reduced PTV volume and four showing increased PTV volume compared to the initial assessment. Tumors mainly moved in the superior-inferior (SI) direction, and there were significant differences in SI movement across all lobes (P<0.001).The short-term efficacy results demonstrated either partial relief or stability. All patients had 100% disease control within 3 months. During the follow-up, 6 early-stage patients, 7 locally advanced-stage patients, and 11 advanced-stage patients experienced progression. Follow-up results indicated that none of the patients experienced severe adverse reactions. Early-stage patients had an objective response rate of 50%, while locally advanced-stage patients had a rate of 66.7% and advanced-stage patients had a rate of 33.3%. For advanced-stage patients, the risk factor related to PFS is BED, while in advanced patients, BED and combination therapy are risk factors associated with PFS.

Conclusion: MR-guided hypo-fractionated radiotherapy can effectively and safely meet clinical requirements for treating non-small cell lung cancer.